3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
17
Recruiting
7
Withdrawn
4
Terminated
2
Active not recruiting
2
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Interventions
Specimen Handling
16
Biopsy
10
Magnetic Resonance Spectroscopy
8
Cyclophosphamide
8
venetoclax
5
Etoposide
4
Azacitidine
4
fludarabine phosphate
3
durvalumab
3
X-Rays
3
Tacrolimus
3
Paclitaxel
3
Interleukin-2
3
Carboplatin
3
zanubrutinib
2
prednylidene
2
fludarabine
2
deltacortene
2
aldesleukin
2
Vincristine
2
Rituximab
2
Radiotherapy, Intensity-Modulated
2
Protein Subunit Vaccines
2
Prednisone
2
Nivolumab
2
Melphalan
2
Injections
2
Gemcitabine
2
E 7107
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Suspended
×
talazoparib
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled